BOLT · Bolt Biotherapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on BOLT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About BOLT · Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Live Quote
SELL (score -8) · 12-1 mom -17.9% · RSI 43 · below_both · -39.8% from high
Targets blend Wall Street consensus (2 analysts: low $7.00 / mean $41.00 / high $75.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
BOLT is a clinical-stage cancer immunotherapy biotech with ~$23.9M cash (burning ~$8-11M/quarter), facing a going-concern qualification as of Q1 2026 and less than four quarters of runway at current burn rates. A recent cluster of four Form 4 filings (June 10, 2026) for directors LaPorte, Dupont, O'Callaghan, and Onetto triggered the investigation — but all proved to be standard annual board option grants (5,000 shares each at $4.43 strike, vesting June 2027), not open-market purchases. One genuine open-market P-code purchase was found: CEO/President William P. Quinn bought 125 shares on December 5, 2025 at ~$4.607, but this is a de minimis amount (~$576). There are no listed options available and IV cannot be computed. BDC-4182 Phase 1/2 data expected Q3 2026 could serve as a catalyst, but with going-concern risk, near-zero institutional confidence (only 2 analysts), and $22M in net debt, this is an extremely distressed micro-cap with no actionable asymmetric setup.